布地奈德联合异丙托溴铵治疗COPD的效果及对血清炎症因子和免疫功能的影响  

Effect of Budesonide Combined with Ipratropium Bromide in the Treatment of COPD and its Impact on Serum Inflammatory Factors and Immune Function

作　　者：邓世华[1] 姚芳斌 DENG Shihua;YAO Fangbin(Department of Laboratory Medicine,Fuzhou First People's Hospital,Fuzhou 344000,China;不详)

机构地区：[1]抚州市第一人民医院检验科,江西抚州344000

出　　处：《中国医学创新》2025年第12期64-68,共5页Medical Innovation of China

基　　金：抚州市科学技术局项目【抚科社字(2023)7号14号】。

摘　　要：目的:分析布地奈德联合异丙托溴铵治疗慢性阻塞性肺疾病(COPD)的效果及对患者血清炎症因子和免疫功能的影响。方法:选择2023年6月—2024年6月抚州市第一人民医院收治的68例COPD患者。按随机数字表法分为两组,各34例。两组均给予常规治疗(如氧疗、支气管扩张剂等),在此基础上对照组用雾化吸入异丙托溴铵治疗,治疗组在对照组基础上加用布地奈德。对比两组临床疗效、治疗前后肺功能指标[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、呼气流量峰值(PEF)]、血清炎症因子[C反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)]、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+)和CD4^(+)/CD8^(+))及不良反应发生率。结果:治疗组总有效率显著较对照组高(P<0.05);治疗后,治疗组肺功能指标水平均较对照组高,CRP、IL-6、IL-8水平均较对照组低(P<0.05);治疗后,治疗组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均较对照组高,CD8^(+)较对照组低(P<0.05);两组治疗期间均无不良反应发生。结论:布地奈德联合异丙托溴铵治疗COPD的效果较为显著,可有效抗炎调控,显著降低患者血清炎症因子水平,减轻气道炎症高反应,改善患者肺功能,促进机体免疫调节,能够为COPD的治疗提供临床指导与依据,且联合用药安全性较高。Objective:To analyze the effect of Budesonide combined with Ipratropium Bromide in the treatment of chronic obstructive pulmonary disease(COPD)and its effects on serum inflammatory factors and immune function.Method:A total of 68 COPD patients treated in Fuzhou First People's Hospital from June 2023 to June 2024 were selected.They were divided into two groups according to random number table method,with 34 cases in each group.Both groups were given conventional treatment(such as oxygen therapy,bronchodilator,etc.),on the basis of which the control group was treated with atomized inhalation of Ipratropium Bromide,and the treatment group was treated with Budesonide on the basis of the control group.The clinical efficacy,pulmonary function indexes[forced expiratory volume in the first second(FEV1),forced vital capacity(FVC),peak expiratory flow(PEF)],serum inflammatory factors[C reactive protein(CRP),interleukin-6(IL-6),interleukin-8(IL-8)],immune function factors(CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+))before and after treatment and adverse reactions were compared between the two groups.Result:The total effective rate of treatment group was significantly higher than that of control group(P<0.05).After treatment,the levels of lung function indexes in the treatment group were higher than those in the control group,and the levels of CRP,IL-6 and IL-8 were lower than those in the control group(P<0.05).After treatment,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in treatment group were higher than those in control group,and CD8^(+)was lower than that in control group(P<0.05).No adverse reactions occurred in both groups during treatment.Conclusion:Budesonide combined with Ipratropium Bromide has a relatively significant effect in the treatment of COPD,which can effectively reduce the levels of serum inflammatory factors,reduce the hyperinflammatory response of airway,improve the lung function of patients,promote the body's immune regulation,and provide clinical guidance and basis for the treatment of COPD,and the combination of dru

关 键 词：慢性阻塞性肺疾病 布地奈德 异丙托溴铵 雾化吸入 炎症因子 免疫功能 

分 类 号：R563.9[医药卫生—呼吸系统]